MASH UP? Liver disease could be the next big market

MASH UP?

Liver disease could be
the next big market

Big pharma are dishing out billions to buy or license them: in 2023, Pfizer paid $43 billion for Seagen, AbbVie stumped up over $10 billion for ADC pioneer ImmunoGen, and Merck forked out $4 billion up-front – and potentially up to $22 billion –...Contents

MASH UP?
Liver disease could be the next big market

EVALUATING
Key Players

HOW WE HELP